Syntheses of N3-substituted thymine acyclic nucleoside phosphonates and a comparison of their inhibitory effect towards thymidine phosphorylase

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 4, 2008, Pages 1364-1367

  Pomeisl, Karel ^a   Holý, Antonín ^a   Votruba, Ivan ^a   Pohl, Radek ^a  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Acyclic nucleoside phosphonates; Alkylation; Fluorination; Pyrimidine; Thymidine phosphorylase

Indexed keywords

1 [2 (PHOSPHONOMETHOXY)ETHYL]THYMINE; 1 [3 FLUORO 2 (PHOSPHONOMETHOXY)PROPYL]THYMINE; 1 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL]THYMINE; ALKYL GROUP; ANTINEOPLASTIC AGENT; THYMIDINE PHOSPHORYLASE; THYMINE ACYCLIC NUCLEOSIDE PHOSPHONATE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ENZYME INHIBITOR; PHOSPHONIC ACID DERIVATIVE; PYRIMIDINE NUCLEOSIDE; THYMINE;

ALKYLATION; ANIMAL CELL; ARTICLE; CHEMICAL MODIFICATION; CYTOSTASIS; DRUG STRUCTURE; ENZYME INHIBITION; ESCHERICHIA COLI; LYMPHOMA; NONHUMAN; PLACENTA; ANIMAL; CRICETULUS; DRUG ANTAGONISM; ENZYMOLOGY; HAMSTER; HUMAN; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; T CELL LYMPHOMA;

CRICETULUS GRISEUS; ESCHERICHIA COLI;

ANIMALS; CRICETINAE; CRICETULUS; ENZYME INHIBITORS; HUMANS; LYMPHOMA, T-CELL; PHOSPHONIC ACIDS; PLACENTA; PYRIMIDINE NUCLEOSIDES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE PHOSPHORYLASE; THYMINE;

EID: 39049090517     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.01.006     Document Type: Article

References (23)

1. Holý A. Curr. Pharm. Design 9 (2003) 2567
2. Holý A. In: Chu C.K. (Ed). Recent Advances in Nucleosides: Chemistry and Chemotherapy (2002), Elsevier, Amsterdam 167
3. Esteban-Gamboa A., Balzarini J., Esnouf R., De Clercq E., Camarasa M.-J., and Pérez-Pérez M.-J. J. Med. Chem. 43 (2000) 971
4. Friedkin M., and Roberts D.W. J. Biol. Chem. 207 (1954) 245
5. Miyazono K., Okabe T., Urabe A., Takaku F., and Heldin Ch. J. Biol. Chem. 262 (1987) 4098
6. Usuki K., Sarasi J., Waltenberger J., Miyazono K., Pierce G., Thomason A., and Heldin Ch. Biochem. Biophys. Res. Commun. 184 (1992) 1311
7. Furakawa T., Yoshimura A., Sumizawa T., Haraguchi M., Akiyama S., Fukui K., Ishizawa M., and Yamada Y. Nature 356 (1992) 668
8. Haraguchi M., Miyadera K., Uemura K., Sumizawa T., Furukawa T., Yamada K., Akiyama S., and Yamada Y. Nature 368 (1994) 198
9. Matsushita S., Nitanda T., Furukawa T., Sumizawa T., Tani A., Nishimoto K., Akiba S., Miyadera K., Fukushima M., Yamada Y., Yoshida H., Kanzaki T., and Akiyama S. Cancer Res. 59 (1999) 1911
10. Balzarini J., Degréve B., Esteban-Gamboa A., Esnouf R., De Clercq E., Engelborghs Y., Camarasa M.-J., and Pérez-Pérez M.-J. FEBS Lett. 483 (2000) 181
11. Votruba I., Pomeisl K., Tloušt'ová E., Holý A., and Otová B. Biochem. Pharmacol. 69 (2005) 1517
12. Pomeisl K., Pohl R., Holý A., and Votruba I. Collect. Czech. Chem. Commun. 70 (2005) 1465
13. Pomeisl K., Votruba I., Holý A., and Pohl R. Collect. Czech. Chem. Commun. 71 (2006) 595
14. Klein R.S., Lenzi M., Lim T.H., Hotchkiss K.H., Wilson P., and Schwartz E.L. Biochem. Pharmacol. 62 (2001) 1257
15. Nencka R., Votruba I., Hřebabecký H., Tloušt'ová E., Horská K., Masojídková M., and Holý A. Bioorg. Med. Chem. Lett. 16 (2006) 1335
16. Norman R.A., Barry S.T., Bate M., Breed J., Colls J.G., Ernill R.J., Luke R.W.A., Minshull C.A., McAlister M.S.B., McCall E.J., McMiken H.H.J., Paterson D.S., Timms D., Tucker J.A., and Pauptit R.A. Structure 12 (2004) 75
17. Voet D., and Voet J.G. Biochemistry (1990), John Wiley & sons Inc 795 809
18. Noell C.W., and Cheng C.C. J. Heterocycl. Chem. 3 (1966) 5
19. 7P 433.2103: Found 433.2099.
20. 6P 277.0753: Found 277.0762.
21. Ref.6 The reaction was carried out at 37 °C for 10 min and stopped by spotting a 2 μl aliquot onto Silica gel 60 F254 plate that had been prespotted with 0.01 μmol of each thymine and thymidine. The plate was developed in the non-aquaeous phase of the solvent system ethyl acetate/water/formic acid (60:35:5). The spots were visualised under UV light (254 nm) and cut out for radioactivity determination in the toluene-based scintillation cocktail.
22. Cytostatic activity assays. L1210 cells, CCRF-CEM cells, and HL-60 cells were cultivated in RPMI 1640 medium supplemented with calf foetal serum using 24-well tissue culture plates. The endpoint of the cell growth was 72 h following the drug addition. Cells were then counted in Celtac MEK 5208 (NIHON KOHDEN) haematological analyzer. HeLa S3 cells were seeded to 24-well dishes in RPMI 1640 HEPES modification with foetal calf serum. 48 h following the drug addition the cultivation was stopped and the cell growth was evaluated after methylene blue addition.
23. Hocek M., Holý A., Votruba I., and Dvořáková H. J. Med. Chem. 43 (2000) 1817